NewLink Genetics Corporation Appoints Brian Wiley as Chief Commercial Officer
08 janv. 2016 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Jan. 08, 2016 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Completes Enrollment of Phase 3 PILLAR Trial Evaluating Algenpantucel-L for Patients With Locally Advanced Pancreatic Cancer
15 déc. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Dec. 15, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Presents Preliminary Safety Data From Randomized Phase 2 Trial of Indoximod, an IDO Pathway Inhibitor, at San Antonio Breast Cancer Symposium
10 déc. 2015 08h30 HE
|
Lumos Pharma, Inc.
AMES, Iowa and SAN ANTONIO, Dec. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and...
NewLink Genetics Corporation Reaches Enrollment Goal for Randomized Phase 2 Trial of Indoximod for Patients With Metastatic Breast Cancer
10 déc. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Dec. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics to Present at the 27th Annual Piper Jaffray Healthcare Conference
27 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 27, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Announces Clinical Data on Indoximod/Temozolomide Combination in Glioblastoma at Society for Neuro-Oncology Meeting
23 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 23, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Announces Phase 2 Data on Indoximod at the San Antonio Breast Cancer Symposium
13 nov. 2015 16h30 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
Paolo Pucci and Nicholas Vahanian Appointed to Board of Directors of NewLink Genetics
13 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 13, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...
NewLink Genetics Corporation Supports 2015 World Pancreatic Cancer Day
10 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 10, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of developing and commercializing novel immuno-oncology...
NewLink Genetics Corporation Announces Promising Clinical Data on Indoximod at the Society for Neuro-Oncology Annual Meeting
09 nov. 2015 07h00 HE
|
Lumos Pharma, Inc.
AMES, Iowa, Nov. 09, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company at the forefront of discovering, developing and commercializing novel...